OX40/OX40L Costimulatory Pathway: A Potential Therapeutic Target for Allergic Contact Dermatitis?

Walter Liszewski, Naiem Issa

Abstract readEditorial

In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Walter LiszewskiDr. Liszewski is with the Department of Dermatology and the Department of Cancer Epidemiology, Northwestern University, Chicago, Illinois.

Naiem IssaDr. Issa is with Forefront Dermatology, Vienna, Virginia; the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, and the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OX40 and OX40L inhibitors represent the next generation of therapies to treat atopic dermatitis. However, because to their unique mechanism, they have tremendous potential to treat allergic contact dermatitis. Although the cornerstone of allergic contact dermatitis management is allergen avoidance, it is not possible in all cases. In this article, we outline the immunology of these drugs and how they could be leveraged to treat refractory allergic contact dermatitis.

Indexed as

ACDallergic contact dermatitiscontact dermatitisEczemaOX40OX40Lpatch testing

Identifiers

PMID42761973

PMCPMC13588484

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.